RBC Capital Markets reported on CRH Medical (TSE:CRH), stepping up its target to $8.50 earlier today
- Updated: November 28, 2016
RBC Capital Markets bumped up the target of CRH Medical (TSE:CRH) to $8.50 stating a potential upside of 0.17%.
On 12/14/2015, Acumen Capital released a statement for CRH Medical (TSE:CRH) maintained the target price at $5.00 that suggested an upside of 0.60%.
Boasting a price of $7.27, CRH Medical (TSE:CRH) traded -10.53% lower on the day. The last closing price is up 42.27% from the 200-day moving average, compared to the S&P 500 which has decreased -0.03% over the same time period. The company has recorded a 50-day moving average of $6.74 and a 200-day moving average of $5.26. 893,293 shares of the stock traded hands, up from an average trading volume of 376,952
See Chart Below
CRH Medical has a 52 week low of $2.98 and a 52 week high of $8.48 with a P/E ratio of 76.33 The company’s market cap is currently $0.
In addition to RBC Capital Markets reporting its stock price target, a total of 7 analysts have released a report on CRH Medical. The 12-month price target is $5.99 with three analysts rating the company a strong buy, four analysts rating the company a buy, zero analysts rating the company a hold, zero analysts rating the company a underperform, and lastly zero analysts rating the company a sell.
General Company Details For CRH Medical (TSE:CRH)
CRH Medical Corporation, formerly Medsurge Medical Products Corp., is a healthcare products and services company. The Company operates through segments, including the sale of medical products and the provision of anesthesia services. The Company specializes in the treatment of hemorrhoids utilizing its treatment protocol and technology. The Company also provides anesthesiology services to gastroenterologists in the southeastern United States through its subsidiaries. The Company's product distribution strategy focuses on physician education, patient outcomes, and patient awareness. The Company's first product, the CRH O'Regan System, is a single use, disposable, hemorrhoid banding technology for treating hemorrhoid grades I – IV. It principally operates in the United States. It distributes the CRH O'Regan System to physicians. The Company's subsidiary, Gastroenterology Anesthesia Associates, LLC, provides anesthesiology services for gastroenterology procedures.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.